Oculis Holding AG [OCS] vs Regeneron [REGN] Detailed Stock Comparison

Oculis Holding AG

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Oculis Holding AG wins in 4 metrics, Regeneron Pharmaceuticals, Inc. wins in 14 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Oculis Holding AG Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 63.63 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 6.45 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 1.18 9.51 Oculis Holding AG
PEG Ratio -1.71 -4.80 Oculis Holding AG
EV/EBITDA -17.23 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -5,020.20% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -73.45% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -28.65% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-67.69M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 16.71% 25.39% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) 1,346.84 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $1.79B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 1,171.12 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-2.43 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.21 0.40 Oculis Holding AG
Short % of Float 0.95% 2.55% Oculis Holding AG

Oculis Holding AG vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

OCS
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Oculis Holding AG6.92%-55.62%-53.50%-52.34%-30.81%-34.30%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Oculis Holding AG16.71%106.18%120.60%134.26%134.26%134.26%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Oculis Holding AG vs Regeneron Pharmaceuticals, Inc.

MetricOCSREGN
Market Information
Market Cap i$1.55B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i392,447642,495
90 Day Avg. Volume i295,849617,765
Last Close$13.14$618.95
52 Week Range$11.70 - $34.47$476.49 - $821.11
% from 52W High-61.89%-24.62%
All-Time High$34.13 (May 11, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-61.50%-48.90%
Growth Metrics
Quarterly Revenue Growth136.00%0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i-50.20%0.23%
Return on Equity (TTM) i-0.73%0.15%
Debt to Equity (MRQ) i1.189.51
Cash & Liquidity
Book Value per Share (MRQ)$4.32$304.65
Cash per Share (MRQ)$3.67$83.86
Operating Cash Flow (TTM) i$-84,485,882$4.98B
Levered Free Cash Flow (TTM) i$-55,658,724$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Oculis Holding AG vs Regeneron Pharmaceuticals, Inc.

MetricOCS (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i63.6318.00
Forward P/E i-12.8614.21
PEG Ratio i-1.71-4.80
Price to Sales (TTM) i1,346.845.50
Price to Book (MRQ) i6.452.45
Market Capitalization
Market Capitalization i$1.55B$80.98B
Enterprise Value i$1.79B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i1,171.124.95
Enterprise to EBITDA i-17.2316.72
Risk & Other Metrics
Beta i0.210.40
Book Value per Share (MRQ) i$4.32$304.65

Financial Statements Comparison: Oculis Holding AG vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOCS (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i57.09M5.85B
Operating Income (EBIT) i-81.67M3.70B
Operating Margin i-25.8%
EBITDA i-79.36M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-99.14M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax i-186,000725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-98.96M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricOCS (2025)REGN (2025)
Cash & Equivalents i81.33M3.12B
Total Current Assets i218.89M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i36.75M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i1.81M2.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i196.07M31.26B
Retained Earnings i-384.51M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i3.16M1.54B

Cash Flow Statement Comparison

MetricOCS (2025)REGN (2025)
Operating Cash Flow i-78.64M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures i-301,0000
Free Cash Flow i-67.69M3.77B
FCF Margin i-26.3%
Debt Repayment i-373,000N/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricOCSREGN
Shares Short i473,9252.55M
Short Ratio i1.294.46
Short % of Float i0.95%2.55%
Shares Outstanding i57.98M105.72M
Float Shares i49.91M98.55M
% Held by Insiders i4.27%1.98%
% Held by Institutions i52.71%91.08%
% Held by Public i43.02%6.94%

Dividend Analysis & Yield Comparison: Oculis Holding AG vs Regeneron Pharmaceuticals, Inc.

MetricOCSREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026